



Cite this: *Polym. Chem.*, 2024, **15**, 2437

Rational design of polymer-based mRNA delivery systems for cancer treatment

Qianyu Wan,^{a,b} Yuji Sun,^a Xuanrong Sun^b and Zhuxian Zhou^a

Messenger RNA (mRNA)-based cancer therapeutics have shown great promise in cancer prevention and treatment, such as mRNA cancer vaccines and protein replacement therapeutics. The key to mRNA cancer therapeutics is to develop safe and effective delivery systems that can efficiently encapsulate mRNA, protect them from degradation, selectively target specific tissues, facilitate cellular uptake and endosomal escape, and ultimately release them into the cytoplasm for protein expression. Polymer-based mRNA delivery systems have received increasing attention for cancer therapy due to their virtues of customizable chemical structures, easy functionalization, and controllable stability, allowing the overcoming of tumor delivery barriers and enhancing therapeutic efficacy. This review introduces the characteristics and applications of mRNA therapeutics, the principles, and classification of polymer-based mRNA delivery systems, and summarizes several advanced mRNA delivery strategies to realize cancer-selective and intracellular delivery, organ-targeted delivery, and tissue-penetrating delivery. The review aims to provide guidance for the design of future polymer-based cancer mRNA delivery systems.

Received 23rd February 2024,
Accepted 13th May 2024
DOI: 10.1039/d4py00206g
rsc.li/polymers

1. Introduction

Messenger RNA (mRNA) is a single-stranded ribonucleic acid that is transcribed from a DNA strand, which carries the coding information for protein synthesis and can be further transcribed and processed into functional proteins.¹ mRNA is in a special position in the process of information transfer, it expresses the target protein or antigen in the organism according to the central dogma, so that it becomes the “key” to unlock a variety of diseases, thus realizing the purpose of treatment or immunoprophylaxis.² mRNA therapy has several advantages over traditional therapies. mRNA is safer than DNA drugs as it does not integrate into the host genome.^{3,4} Secondly, mRNA can produce proteins that are difficult to synthesize *in vitro* and can be targeted to specific receptors or the circulatory system.⁵ Moreover, mRNA sequences are highly modifiable and can be rapidly updated and iterated. As a result, mRNA-based cancer therapies have specific applications in cancer prevention and treatment. The common principle of mRNA-based cancer therapies is that mRNA is

successfully translated into proteins to inhibit tumor growth or to induce or enhance anti-tumor immune responses. For example, mRNA cancer vaccines can encode specific tumor antigens that activate immune responses. Delivery of essential tumor suppressor mRNA can greatly improve the expression level of tumor suppressor protein and regulate the tumor microenvironment (TME). Encoding Cas 9 with mRNA reduces off-target effects and genotoxicity while encoding chimeric antigen receptor (CAR) or T cell receptor (TAR) with mRNA increases transfection rates and reduces mutation risk (Fig. 1).^{6–9}

Nevertheless, the single-stranded structure of the mRNA molecule, which is different from DNA.^{10–12} Naked mRNA is highly susceptible to destruction by nucleases or hydrolases in blood or body fluids and is rapidly cleared by the kidneys. Unprotected mRNA has been reported to have an extremely short metabolism or systemic half-life of less than 3.8 minutes.¹³ Second, it is also challenging for mRNA with certain physicochemical characteristics-like being hydrophilic and negatively charged-to get through the cell membrane and enter the cytoplasm. Additionally, mRNA is usually internalized and trapped in acidic endo-lysosomes, where it is degraded by enzymes, restricting its genetic tasks. Therefore, the development of mRNA carriers to get around the challenges above is the key to effective mRNA delivery. Various delivery systems have been developed for mRNA delivery, including viral vectors^{14,15} and non-viral vectors.^{16,17} Viral vectors utilize genetic engineering technology to modify

^aZhejiang Key Laboratory of Smart Biomaterials and Key Laboratory of Biomass Chemical Engineering of Ministry of Education, College of Chemical and Biological Engineering, Zhejiang University, Hangzhou, 310027, China.

E-mail: zhouzx@zju.edu.cn

^bCollaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals and College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, China. E-mail: sunxr@zjut.edu.cn




Fig. 1 Strategies of mRNA-based therapeutics for cancer treatment.

viruses as carriers for exogenous gene delivery. Viral vectors mainly consist of retroviruses,¹⁸ lentiviruses,¹⁹ and adenoviruses,²⁰ which have the advantages of high transfection efficiency and a high expression level of exogenous genes. However, viral vectors have disadvantages of high immunogenicity,²¹ carcinogenicity risk,²² limited capacity of encapsulated drugs,²³ and complicated operation of the preparation process.²³ Non-viral mRNA delivery vectors, including lipid-based nanoparticles (NPs),²⁴ polymeric NPs,²⁵ inorganic NPs,²⁶ and biomimetic NPs,²⁷ have been engineered with many favorable properties such as biocompatibility,²⁸ controlled targeting,^{28,29} low immunogenicity, and high safety.³⁰ However, non-viral mRNA delivery vectors are still limited in gene transfection efficiency compared to the natural viral vectors, holding a great challenge to improve the delivery efficiency.

Polymers have been exploited as a major type of non-viral gene delivery carrier, with the merits of simple synthesis, diverse structure, and easy functionalization.^{31,32} Therefore, they have been widely used for gene delivery of DNA, mRNA, siRNA, *etc.* (Fig. 2).^{33–35} Positively charged polymers can electrostatically bind to negatively charged mRNA and form multimeric complexes at physiological pH, protecting the mRNAs from degradation and facilitating intracellular delivery.^{36,37} In addition, covalent attachment of mRNA to polymers can also be achieved through the use of degradable linkers.³⁸ The systemic delivery of mRNA by polymers involves several steps (Fig. 3): (1) target and accumulate in specific organs and tissues; (2) entry into the cell by endocytosis; (3) endosome escape; (4) intracellular release, and (5) translation into protein.^{39–41}

This review summarizes representative non-viral polymeric vectors for mRNA cancer delivery. We highlight the recent advance of polymer-based mRNA delivery systems for enhanced cell entrance and cancer cell-selective delivery, organ-targeted delivery, and tissue-penetrating delivery.

2. Polymer-based nonviral vectors for cancer mRNA delivery

Polymer molecules are usually able to load by electrostatic adsorption with mRNA. An optimal polymer-based mRNA delivery system should: (1) efficiently encapsulate and protect mRNA from nuclease degradation; (2) possess high biocompatibility and safety; (3) promote the penetration and accumulation of specific cells, tissues, and organs; (4) avoid lysosomal degradation in intracellular translocation pathways; (5) enhance the release of mRNA in the cytoplasm to exert the desired effect. In this section, different types of polymer-based delivery of mRNA will be discussed, including polyplexes, lipo-polyplexes, *etc.* (Fig. 4, Table 1).

2.1 Polyplex

A commonly used vector for delivering nucleic acids is polyplex (*i.e.* polymeric NP). Polyplex protects nucleic acids from enzymatic degradation and promotes cellular uptake.⁴² Compared to cationic liposome-based systems, polyplex systems offer a high degree of versatility by controlling molecular weight, structure and composition.⁴³ Commonly used polyplexes as nucleic acid vectors are polyethyleneimine (PEI), polyester, poly(amino acids), *etc.*




Fig. 2 An overview of polymer-based mRNA delivery for cancer treatment.




Fig. 3 Schematic representation of polymer-based mRNA delivery systems to overcome the systemic biological barriers.




Fig. 4 Overview of polymeric vector backbones and features for mRNA delivery.

Table 1 The optimal polymer-based mRNA delivery systems for cancer therapy

Polymer backbone	Cancer/tissue	Related mRNA	Size (nm)	Zeta potential (mV)	Ref.
F-PEI	Melanoma	MC38-encoded mRNA	280.0	-6.5/-12.3	50
β -CD-PEI	—	OVA-encoded mRNA	234.7 \pm 3.5	47.3 \pm 3.6	51
PEG-PEI	L929 fibroblasts (<i>in vitro</i>)	Luciferase (Luc) mRNA	103.0 \pm 7.7	—	54
PLGA	p53-deficient hepatocellular carcinoma	p53-encoded mRNA	105.0 \pm 0.1	-8.1 \pm 2.0	61
PBAE	Mammary carcinoma	4-1BB/IL-12-encoded mRNA	100.0 \pm 20.0	23.0 \pm 2.0	65
PBAE	Ovarian carcinoma	IRF5/IKK β -encoded mRNA	99.8 \pm 24.5	3.4 \pm 2.2	70
APE	—	Luc mRNA	120.0 \pm 30.0	5.0 \pm 3.0	71
PACE	—	Deglycosylation-dependent Renilla Luc/firefly Luc (FLuc)-encoded mRNA	210.4	9.9	72
PAsp	—	Cy5-mRNA	110.0	20.0	82
PAMAM	—	Cy5-EGFP mRNA	133.2	34.2	90
PHTA	Melanoma	mOVA-encoded mRNA	130.0 \pm 6.0	25.0 \pm 7.0	35
Trimannose	Cervical cancer	N1m ψ nucleoside modified mRNA	235.7 \pm 4.7	46.0 \pm 2.1	92
Lipid shell-PBAE	Melanoma	OVA-encoded mRNA	50.0	—	93
Lipid shell-dendrimer	Breast carcinoma	Luc mRNA	138 \pm 1.5	-1.0 \pm 0.4	94

2.1.1 PEI. PEI is a cationic polymer with a high positive charge density, which enables PEI to adsorb mRNA through strong electrostatic binding.⁴⁴ It was reported that the relatively high transfection efficiency of PEI vectors is due to their ability to avoid translocation to degrading lysosomes.⁴⁵ According to the “proton sponge” hypothesis, the buffering capacity of PEI leads to osmotic swelling and endosomal rupture, resulting in the release of the carrier into the cytoplasm.⁴⁶ PEI also has immunostimulatory effects, such as stimulating dendritic cells (DCs) activation and promoting cytokine production.⁴⁷

The particle size and the surface charge are the main factors affecting the bioactivity and biocompatibility of PEI-based complexes. PEIs with molecular weights between 10 and 30 kDa are severely cytotoxic despite their high mRNA delivery efficiency, whereas PEIs with molecular weights below 1.8 kDa are ineffective, thus limiting their potential for biological applications.^{48,49} Efforts have been made to improve the delivery efficiency and biocompatibility of PEI. Li *et al.*⁵⁰ synthesized fluoroalkane-grafted polyethyleneimine (F-PEI) for mRNA delivery that promoted intracellular delivery of mRNA and activated the Toll-like receptor 4 (TLR4)-mediated signaling pathway. This nanovaccine without additional adjuvants induced DCs maturation, triggered efficient antigen presentation and anti-tumor immune responses, and delayed the growth of established B16-OVA melanomas. Tan *et al.*⁵¹ prepared β -CD-coupled branched PEI (2 kDa) to improve the delivery efficacy of mRNA delivery. This CD-PEI coupler-based mRNA vaccine platform also facilitated the escape of mRNA molecules across the plasma membrane and from endosomes, ensuring high transfection efficiency. Modification of polyethyleneglycol (PEG) to polycations can reduce cytotoxicity and improve the solubility and stability of colloidal complexes.⁵² PEG fragments like a corona prevent aggregation of the complexes and reduce the adsorption of serum, thus improving the solubility and stability.⁵³ Debus *et al.*⁵⁴ first studied the PEG (20 kDa) modified PEI (25 kDa) for mRNA delivery. The results showed PEGylation significantly improved colloidal stability but also reduced transfection efficiency.

Although the stability and delivery efficiency of PEI-based mRNA vectors can be improved after chemical modification, the clinical application is still hindered by their non-degradability and relatively poor biocompatibility. For example, excessive stability of PEI-mRNA complexes would result in limited release of their loaded mRNAs, thereby affecting their translation efficiency. Therefore, it is important to develop polymeric carriers with good biodegradability and biocompatibility for mRNA delivery. In future studies, when considering the use of PEI as an mRNA delivery vector, its dosage can be rationalized to ensure effective cellular uptake and avoid unnecessary cytotoxicity. In addition, changing the molecular weight of PEI is also a feasible strategy to reduce cytotoxicity. Introducing degradable chemical bonds, such as disulfide bonds, into the PEI structure would provide a pathway for mRNA to be degraded more readily, thereby reducing the potential impact on the organism.⁵⁵ Meanwhile, modification

of the surface of PEI, for example, through chemical modification or physical cross-linking, could enhance its affinity for the target cells, thereby improving the efficiency of mRNA delivery.^{50,51,56}

2.1.2 Polyesters. Polyesters are excellent in biocompatibility, biodegradability, and biosafety, and have been widely applied as biomedical materials.⁵⁷ A variety of polyesters have been used for mRNA delivery in cancer therapy, such as poly(lactic-*co*-glycolic acid) (PLGA), poly(*b*-amino esters) (PBAEs), amino polyesters (APEs), and poly(amine-*co*-ester) (PACE).⁵⁸

PLGA is a hydrophobic polyester polymerized from lactic and glycolic acid monomers. The biodegradation rate can be controlled by adjusting the ratio of lactic and glycolic acid and the molecular weights. With this property, PLGA has been widely used as a gene carrier materials for disease treatments, including cancer.^{59,60} Xiao *et al.*⁶¹ reported the combination therapy of a suppressor p53 mRNA-loaded PLGA NP with an immune checkpoint inhibitor (anti-PD-1) for cancer therapy. This strategy induced p53 reprogramming of the TME by NK and CD8 T cell activation, polarized the predominance of tumor-associated macrophages (TAMs) to an anti-tumor phenotype, and inhibited p53-deficient liver tumors growth and metastasis (Fig. 5).

PBAE is a kind of degradable cationic polymer obtained by Michael's addition of primary amine or secondary amine and diacrylate. PBAE can self-assemble in an aqueous solution to form nanoscale discrete structures that enhance the transfection of mRNA.⁶² The surface charge of PBAE can be altered by changing the side chain and terminal groups to increase the buffering capacity and promote cellular internalization.^{63,64} PBAE as a vector can be used for reprogramming the TME to enhance cancer immunotherapy. Neshat and colleagues⁶⁵ used PBAE vectors for the co-delivery of mRNAs encoding immuno-stimulatory cytokine interleukin (IL)-12, the co-stimulatory signaling 2 molecule 4-1BB ligand, and immunostimulatory adjuvants. The platform induced tumor-associated antigen-presenting cells (tAPCs) and activated cytotoxic T effector cells. As antigen-free cancer immunotherapy, the platform utilizes copolymers to control mRNA release and specifically transfect at TME. This localized treatment dramatically lowers the risk of systemic inflammation and toxicity as compared to prior tumor immunotherapies (Fig. 6). To achieve the anti-tumor effect, TAMs can be converted from the M2 to the M1 phenotype by gene editing,^{66,67} but it may trigger systemic inflammation due to non-specificity.^{68,69} To address this challenge, Zhang *et al.*⁷⁰ constructed a PBAE-based system carrying *in vitro*-transcribed mRNA encoded with M1 phenotype transcriptional polarizing factors to reprogram TAMs. The system circumvented the pro-tumor growth and metastatic characteristics of the M2 phenotype and exerted the anti-tumor effects of the M1 phenotype, avoiding systemic toxicity (Fig. 7).

APEs are obtained by ring-opening polymerization of lactones using amino alcohols as initiators. Yan *et al.*⁷¹ synthesized functionalized APE libraries using a thiol-alkene click reaction. To improve the stability of mRNA in serum, the tri-block copolymer F127 was added to protect mRNA. The results showed that with an increase in the content of the protective




Fig. 5 Illustration of PLGA-based nanotherapeutics loaded with p53 mRNA for combination cancer therapy with an anti-PD-1 immune checkpoint inhibitor.⁶¹ Copyright 2022, adapted with permission from Springer Nature.




Fig. 6 Illustration of PBAE-based delivery system carrying *in vitro*-transcribed mRNA to reprogram TAMs to an anti-tumor M1 phenotype for cancer immunotherapy.⁶⁵ Copyright 2023, Elsevier.

coating, the stability of mRNA was enhanced, but the delivery efficiency was decreased. Therefore, it is necessary to fully balance the relationship between the protective effect and the delivery efficiency when designing the mRNA delivery system.

PACEs are synthesized from three monomers by enzymatic reaction: cationic diol monomer, lactone monomer and diacid monomer. Their roles are to participate in the primary electrostatic interaction with nucleic acid, stabilize the complex through hydrophobic interaction, and form biodegradable ester bonds with the other two monomers.^{72,73} Endosomal

escape is a critical step in the intracellular drug delivery of mRNA.⁷⁴ To rationally optimize the mRNA transfection efficiency of polymeric material libraries, Jiang *et al.*⁷² optimized the mRNA transfection efficiency of PACE material libraries and found that mRNA encapsulation efficiency and endosomal escape are determinants of transfection efficiency rather than uptake.

Polyester has great potential in the field of delivering mRNA due to its good biodegradability and biocompatibility. Polyester with functional groups can deliver mRNA therapeutics specifically into immune cells to induce a strong immune response.⁷⁵ However, a series of technical challenges need to be overcome to effectively encapsulate mRNA in polyesters. Due to the significant differences between mRNA and polyesters, such as hydrophobicity/hydrophilicity, this leads to repulsion problems when they come into contact with each other. These properties make precise control of polyesters loading on mRNA a complex task. Therefore, specific strategies are needed to address these potential obstacles to ensure that the mRNA can be stabilized and perform its function under appropriate conditions. For example, one potential strategy is to synthesize analogs of specific mRNAs. Such analogs have complementary base pairing with specific mRNA sequences. Such a design not only ensures the structural stability and biological activity of the mRNA, but also enables efficient mRNA loading in polyesters.⁷⁶

2.1.3 Poly(amino acids). Poly(amino acids) are a class of macromolecules with amino acids and their derivatives as structural units, which can be prepared by ring-opening polymerization of amino acid *N*-carboxyanhydrides. The poly(amino acids) obtained contain amphiphilic block copolymers, thus can generate a specialized core–shell structure. In the




Fig. 7 Schematic representation of the anti-tumor effect of macrophages by editing the TAMs gene M2 to M1 phenotype by the PBAE-based mRNA delivery systems.⁷⁰ Copyright 2019, Springer Nature.

core–shell structure, the hydrophobic core encapsulates the hydrophobic drug through hydrophobic interactions, and the hydrophilic shell extends its circulation.⁷⁷ In the past, poly(amino acid) molecules have been widely used in cancer therapy due to their relatively simple synthesis, unique structural features, and intrinsic bioactivity.^{78,79} The appropriate hydrophobicity of poly(amino acids) is essential for the transfection of mRNA loaded on polyplexes.⁸⁰ In general, octanol–water partition coefficient ($\log P$) is usually used as a parameter of hydrophobicity.⁸¹ Yum *et al.*⁸² created a series of poly(asparagine) (PAsp) derivatives with different hydrophobicity as vectors for mRNA delivery. The results showed that the threshold of the $\log P$ of PAsp derivatives that can effectively transfect mRNA was around -2.4 at pH 7.3. When the $\log P$ was greater than -2.4 , the mRNA expression was 1000-fold different from that when it was less than -2.4 . When the $\log P$ of PAsp derivatives is between -1.8 and -1.3 , it can be realized that mRNA reaches the lungs preferentially after systemic administration.

2.1.4 Dendrimers and other polymers. Dendrimers are a type of branched macromolecule and are recognized as perfect carriers for drug and gene delivery,^{83–85} benefiting from their precise and controllable physicochemical properties,⁸⁶ broad internal cavity structures,⁸⁷ and dense surface-active functional groups.⁸⁸ Polyamidoamine (PAMAM) is one of the most extensively studied dendrimers. However, the application of PAMAM as biomedical materials is limited by their toxicity and low biodegradability, which is influenced by the type and number of terminal functional groups. Many efforts have been made to develop various dendrimers with multifunctionality to enhance gene delivery efficiency and lower toxicity.⁸⁹ Joubert *et al.*⁹⁰ modified PAMAM with *p*-toluenesulfonylarginine modification, which increased the electrostatic, hydrogen bonding and hydrophobic interactions, facilitating multiple interactions and fusion with the cell membrane. This process promotes cellular uptake efficiency and endosomal escape

capacity. The modified PAMAM has a low charge density, which limits its original cytotoxicity. Furthermore, this study indicates that PAMAM's fusogenic group modification and strongly basic peripheral amines are essential for mRNA delivery.

Lipid-based mRNA delivery systems have been reported to elicit strong cytokine responses upon systemic administration, which may be responsible for adverse reactions leading to autoimmune lesions or systemic inflammatory infections.⁹¹ In addition to the types of polymers described in the previous section, several polymeric vectors have been explored to address the problems of lipid-based mRNA delivery systems. Huang *et al.*³⁵ developed a delivery system for amphiphilic alternating poly(*ortho*-hydroxy tertiary amine) (PHTA) copolymers encapsulating mRNA encoding ovalbumin (mOVA). The abundant hydroxyl groups in the copolymers' backbone can chelate with metal ions and inhibit the production of reactive oxygen species (ROS) associated with inflammation, which makes this delivery system delivered *in vivo* without inflammatory side effects. Meanwhile, the vector successfully delivered mRNA cancer vaccines, which triggered strong T-cell-mediated anti-tumor cellular immunity, providing a potential approach for establishing potent mRNA cancer vaccines with a favorable inflammatory safety profile (Fig. 8).

2.2 Lipopolyplex

Lipopolyplex is a bilayer-structured NP with a polymer-encapsulated mRNA as the core and phospholipid as the shell. When it comes to reducing inflammation in lipid-based delivery systems to improve safety, lipopolyplex can be an effective alternative to lipids as they combine the advantages of increased endocytosis efficiency and reduced cytotoxicity.^{92,93} Kris Thielemans' group⁹² studied a lipopolyplex-based mRNA delivery system. The strategy utilizes naturally occurring nucleoside (*e.g.*, *N*1-methylpseudouridine (N1m ψ))




Fig. 8 (a) Synthesis of the alternating copolymer PHTA and schematic construction of an integrated polymer vaccine. (b) Percentage of neutrophils (Neut), eosinophils (Eosi), CD11b DCs, NK and alveolar macrophages (aMac) within CD45 cells in lung tissue. (c) Schematic representation of the therapeutic mechanism of this polymeric mRNA cancer vaccine. (d) Mean tumor growth curves of mice receiving the indicated treatments. (e) Tumor suppression efficiency at endpoint compared to PBS group. (f) Hematoxylin and eosin (H&E) stained images of tumor tissues after B16-OVA tumor-bearing mice received PBS, PHTA-C8/mOVA and PHTA-C18/mOVA, respectively. Scale bar: 100 μ m.³⁵ Copyright 2022, Wiley.

modifications to reduce innate sensing of mRNAs, thereby inhibiting inflammatory cytokine responses. When administered systemically, this lipopolyplex platform demonstrated good hemocompatibility and mostly limited mRNA expression in splenic antigen-presenting cells (APCs). Compared with electroporation and lipid-based delivery systems, immunization with lipopolyplex elicited robust T-cell immunity and showed greater efficacy in modulating tumorigenesis. Persano *et al.*⁹³ encapsulated mOVA in PBAEs' core, which was packaged in a lipid bilayer shell structure. These core-shell NPs were taken up by DCs through macropinocytosis and effectively stimulated the expression of interferon- β and IL-12 in DCs. In treating lung metastatic B16-OVA melanoma, it significantly reduced tumor nodules by more than 90%. This core-shell structure provides a potential platform for mRNA vaccine delivery. Lipopolyplexes-based mRNA delivery systems have made significant advances in cancer therapy. Moreover, platforms applied to tumor detection and imaging are also particularly important when diagnosing cancer. Therefore, developing mRNA delivery systems that can both image tumors and efficiently produce functional proteins is a challenging task. Xiong *et al.*⁹⁴ developed a pH-responsive lipopolyplex-based mRNA delivery system. The system contains PEGylated BODIPY dyes that were used for non-invasive near-infrared (NIR) imaging. The study found that the length of PEG modified in the lipid shell has an effect on mRNA delivery. When PEG length is between 1000–5000 g mol⁻¹, lipopolyplexes are protected from aggregation and non-specific cellular uptake. The study

also demonstrated a relationship between mRNA expression intensity *in vivo* and pK_a at lipopolyplex. When the pK_a is about 6.3, mRNA can usually produce more protein in the liver. The optimal lipopolyplex obtained could successfully mediate mRNA expression in tumors by pH-responsive NIR imaging while illuminating the tumor. The platform is expected to become a suitable method for simultaneous diagnosis and treatment of cancer.

3. Strategies for advanced mRNA delivery

The key to effective mRNA therapy is efficiently delivering mRNA to the target site to produce enough aimed proteins. The off-target of the mRNA will decrease the therapeutic efficacy and increase the toxicity to normal tissues. Therefore, when rationally designing the delivery system to protect mRNA, it is also necessary to consider whether cell-selectivity, organ-selectivity, and penetration of difficult-to-permeate tissues can be achieved during its *in vivo* delivery. Targeting strategies for polymer-based mRNA delivery systems include passive targeting, endogenous targeting, and active targeting.⁹⁵ In cell-selective delivery, surface modification is a commonly used method to confer targeting capabilities to delivery systems. In particular, antibodies, peptides, or other molecules (*e.g.*, ligands) are conjugated to polymeric vectors to achieve selective delivery to cancer cells, DCs, and T cells.⁹⁶ In organ-targeted delivery, the charge of the delivery

system plays a key role. Serum proteins recognize NPs with different charges and adsorb them to the surface. This surface-adsorbed protein interacts with homologous receptors in the target organ to facilitate organ-targeted delivery of mRNA. For example, ionizable NPs can be targeted to the liver, cationic NPs to the lungs, and anionic NPs to the spleen. In hard-to-penetrate tissues, the special physico-chemical properties of NPs can interact with biological barriers. Because of the interaction, they usually show tissue enrichment and a strong ability to penetrate (Fig. 9). This section will discuss advanced strategies for cell-selective, organ-targeted, and tissue-penetrating polymer-based mRNA delivery systems.

3.1 Cancer-selective and intracellular delivery

One of the great challenges in cancer mRNA therapy is the effective targeted delivery of therapeutic genes into cancer cells. Moreover, the mRNA vectors must be able to cross the cell membrane and internalize into the cytoplasm for translation.⁹⁷ Nanocarriers are modified with tumor-homing ligands to realize cancer-selective delivery and improve the internalization rate.^{98,99} For example, Chen *et al.*¹⁰⁰ developed a cyclic Arg-Gly-Asp peptide (cRGD)-modified GFP mRNA polymeric micelle. This system utilizes the ability of cRGD to specifically bind to $\alpha V\beta 3$ and $\alpha V\beta 5$ integrins overexpressed on the membranes of tumor vascular cells and tumor cells. The cRGD-modified polymeric vectors exhibited a 10-fold increase in tumor accumulation and GFP protein expression in the tumor compared to those without the cRGD ligands. The intracellular delivery of the gene vectors can be enhanced by surface chemical modification.

APCs process these neoantigens and present them to effector T cells for triggering and activation.^{101,102} Among them, DCs are the APCs with the strongest antigen-presenting ability, which can take up and process antigens such as tumors or pathogens and deliver them to T cells.¹⁰² Fornaguera *et al.*¹⁰³ prepared an oligopeptide-end modified PBAEs-based mRNA delivery system. This system utilizes cellular phagocytosis and endocytosis to selectively deliver NPs to splenic DCs. Jordan J. Green's group¹⁰⁴ demonstrated that the addition of lipophilic subunits to the PBAE backbone is critical for targeted delivery to DCs. A rational explanation may be that a multitude of innate immune receptors have developed the ability to identify the hydrophobic segment of the molecule. Particles with more hydrophobic surfaces may increase DCs uptake into cells due to interactions with the receptor. Because of this interaction, it allows for cellular uptake and transfection of NPs without PEGylation or targeted ligand modification (Fig. 10).

T cells exert their immune function through lymphatic vessels and blood circulation,¹⁰⁵ and their differentiation checkpoints are important for improving cancer immunotherapy.¹⁰⁶ However, in the treatment of solid tumors, most T cells cannot effectively enter and activate in tumor tissues.¹⁰⁷ Therefore, how to deliver mRNA targeting to T cells and promote their entry into tumors is an urgent problem. To optimize gene delivery for effective regulation of T cells, various cellular immunotherapies have been proposed, such as chimeric antigen receptor T cell (CART) immunotherapy,¹⁰⁸ but there are still potential side effects such as neurological toxicity and cytokine storm.^{109,110} To circumvent the above problems, Paul A. Wender's group¹¹¹ has developed a new CART-




Fig. 9 Schematic representation of advanced mRNA delivery strategies.




Fig. 10 (a) Schematic diagram of a biodegradable PBAE vector system targeted for delivery to splenic DCs. (b) PBAE NPs containing lipophilic side chains exhibit more efficient cellular uptake. (c) In order to observe cellular uptake, NPs' colocalization with endosomes/lysosomes, and GFP transfection, representative pictures of DC2.4 cells labeled with lysosome/endosome dye were taken six hours after treatment with NPs expressing Cy5-labeled GFP-encoding mRNA (scale bars: 20 μ m).¹⁰⁴ Copyright 2023, National Academy of Sciences.

mRNA therapy, namely, charge-altering releasable transporters based on β -amido carbonate (bAC-CARTs). The effects of polymer backbone and side chain spacing on cellular endocytosis have received little attention in previous studies of CARTs. This system used a polymeric backbone to increase the spacing and mobility of lipids, which allowed for better fusion with the cell membrane. The bAC-CARTs convert the initial polycationic CARTs into neutral intermediates, thus enabling lysosomal escape, release, and subsequent translation of the loaded mRNA. In addition, polymer side chain spacing may also affect particle organizing, viscosity, and ion exchange, thus affecting mRNA release. The results showed that the system had 97% spleen targeting. In contrast to previous studies with CARTs, it allows efficient transfection of splenic T cells without targeted ligands and does not cause adverse inflammatory responses.

Notably, due to the sieving effect of biological filtration systems, most NPs are usually engineered to be of the desired size, resulting in a more pronounced accumulation in the corresponding organ.^{112,113} However, they are not targeted for delivery to the corresponding cell populations. Therefore, in addition to focusing on the biodistribution of NPs in organs, but the fate of NPs in different cells within the organ needs to be given more attention. In conclusion, the precise delivery of mRNA to target cells can undoubtedly significantly enhance drug delivery and effectively reduce potential side effects caused by off-target effects. However, the realization of such a targeting strategy is an extremely complex and challenging process. It involves an in-depth understanding of the structure and function of different cells, as well as the specific mechanism of endocytosis of NPs by the cell membrane.^{114,115} In addition, multiple intracellular biological barriers such as endosome escape, mRNA stability, and translation efficiency need to be overcome, all of which may affect delivery efficiency

and safety.^{116,117} Therefore, despite the potential advantages of cellular-level targeting, the road to its implementation is still full of unknowns and challenges.

3.2 Organ-targeted mRNA delivery

The systemic delivery of mRNA to tumors remains a challenge that has not yet been fully resolved. Various polymer-based delivery systems have been designed to deliver mRNA to organs. These polymers may contain many of the accessory lipids present in normal lipid NPs for mRNA delivery, and they frequently exhibit comparable properties to lipid systems.¹¹⁸ After systemic delivery, polymeric NPs can cause mRNA expression in different organs. Furthermore, the mechanisms of polymeric NPs targeting to organs are not well defined. In general, variations in formulation composition, such as regulating the internal and/or external charge of the NPs, will affect their expression levels in different organs.¹¹⁹

The delivery of circulating NPs to the liver is mediated by adsorption to the surface of soluble apolipoprotein E (ApoE), so that NPs encapsulating mRNAs reach the liver preferentially.^{120,121} An especially useful "molecular sieve" is the endothelium of the hepatic sinusoids, which allows NPs smaller than 150 nm to freely enter the Disse space where hepatocytes and hepatic stellate cells are located.^{122,123} In contrast, relatively large NPs are taken up by Kupffer cells surrounding the hepatic sinusoids. However, delivery to the liver through the size of NPs alone is not enough, as the precision of delivery to different cells, tissues, and cancer types in the liver remains to be improved. Using hepatic tumor-specific peptide-modified polymeric vectors is an important strategy to achieve liver-targeted delivery.^{124,125} Lei *et al.*¹²⁶ modified polymer micelles with the hepatocellular carcinoma-specific peptide HCC 167. The HCC 167-modified micelles had more substantial and faster cellular uptake than unmodified micelles. This system

demonstrates that HCC 167 can specifically recognize the alkaline phosphatase placental-like 2 receptors on HepG2 cell membranes, forming a high-affinity receptor-ligand complex for liver targeting.

After systemic delivery, the preferential arrival of NPs to the liver can result in excessive homing effects in the liver. Therefore, organ-targeted delivery strategies are particularly important for optimal efficacy and therapeutic precision. Daniel J. Siegwart's group^{127,128} proposed a selective organ targeting (SORT) strategy. By rationally designing NPs, different ratios of variously charged lipids (called "SORT molecules") were added to the vector formulation. The results showed that mRNA-loaded vectors with different charges were reliably and precisely delivered to the lungs, spleen, and liver of mice, respectively. Additionally, Zhang *et al.*¹²⁹ created a single-component, multifunctional ionizable amphiphilic Janus dendrimer (IAJD)-based mRNA delivery system. The fundamental structure of the hydrophobic region of the IAJD was varied in this by altering the alkyl lengths, and this contributed to a 90.2-fold improvement in the activity of mRNA targeting delivery to the liver, lungs, lymph nodes, and spleen. This result showed that asymmetry in the primary structure of the hydrophobic portion of the vector plays a vital role in organ-target delivery.

Negatively charged polymers and rational modification of polymer side chains enable targeted delivery of mRNA to the spleen.¹³⁰ However, negatively charged polymers alone are difficult to electrostatically adsorb and successfully encapsulate with similarly negatively charged mRNAs, resulting in inefficient preparation and delivery. To address this problem, strategies of zwitterion and charge reversal have emerged. Liu

*et al.*³⁶ reported a cationic polymer zwitterionic phosphorylation modification strategy. This modification strategy produced a serum-stable amphiphilic structure for polyplexes and introduced hydrophobic alkyl chains to help polyplexes fuse with endosomal membranes. The incorporation of negative phosphate groups into the system effectively enhanced the ability of polyplexes to deliver mRNA targeting the spleen and lymph nodes. Compared with the unmodified cationic polyplexes, the optimal system obtained delivered mRNA with a 39 500-fold increase in protein expression (Fig. 11). Shen's group¹⁰ presents an esterase-triggered deionization strategy for the design of quaternium lipid-like molecular systems. The system internalizes into cells *via* macropinocytosis and the clathrin-related pathway. Since the spleen contains appropriate levels of esterase, the system remained stable during circulation and was released in the spleen, allowing for spleen-specific transfection. The system encapsulating mRNA with tumor antigens induced antigen presentation and immune response in APCs and demonstrated effective treatment of melanoma.

After systemic delivery, mRNA accumulates mainly in the liver and spleen. To realize the delivery of mRNA to extrahepatic organs, further studies on the potential targeting delivery mechanisms and methodologies are needed. Qiu *et al.*¹³¹ suggested that it is precisely because NPs selectively adsorb specific plasma proteins upon administration that these surface proteins can act as ligands to target organs. The route of administration plays an important role in facilitating the targeting of NPs to organs.¹³² Therefore, combining particular administration and polymer design will facilitate mRNA organ-targeted delivery. Tang *et al.*¹³³ reported an innovative design




Fig. 11 (a) Schematic representation of phospholipidation action converting cationic polymers into zwitterionic mRNA carriers that are selectively expressed in spleen and lymph nodes. (b) Chemical structures of representative ZPP polymers at physiological pH. (c) Biodistribution quantification of representative Cy5-mRNA polyplexes (Cy5-mRNA dose: 0.25 mg kg^{-1}). (d) Representative Cy5-mRNA polyplexes mediate the quantification of fLuc mRNA expression, mostly in the spleen. (e) Quantification of CD4 T cells, CD8 T cells, B cells and macrophages by flow cytometry of lymph node cells 48 hours after intravenous injection. (f) Representative *in vitro* and *in vivo* organ images of protein expression after delivery of mRNA polyplexes (Fluc mRNA dose: 0.25 mg kg^{-1}).³⁶ Copyright 2021, adapted with permission from the American Chemical Society.

of dual-targeted mRNA nanoformulations based on PBAE and hyaluronic acid. The formulation has ideal stability and efficiently transfects target proteins into lung tissues by inhalation. More importantly, the optimized dual-targeted mRNA-NPs efficiently accumulate in lung tumor cells and inflammatory macrophages, expressing desired proteins like the p53 tumor suppressor, for therapeutic use and effective lung tissue transfection. Similarly, Philip Santangelo's group¹³⁴ evaluated a PBAE-based NP P76, which efficiently delivered various mRNAs to the lungs of different animals *via* nebulized inhalation. The dose of this delivery system was greatly reduced compared to previously reported PBAE. The results showed that the delivery system was safe, well tolerated, and had high protein expression after mRNA transfection, providing an idea for inhalable nucleic acid therapy (Fig. 12).

3.3 Tissue penetrating mRNA delivery

NPs-based drug delivery systems usually need to take the CAPIR five cascade steps (*i.e.* Circulation, Accumulation, Penetration, Internalization, Release).^{135,136} Analysis of the *in vivo* delivery process of NPs reveals that various biological barriers in organisms often hinder the penetration of NPs. At the same time, the delivery of NPs in solid tumors often suffers from low penetration efficiency. Therefore, further

improving the tissue penetration ability of NPs and enhancing their therapeutic efficacy are urgent problems for anti-tumor nanomedicines.

The biological barrier of TME is a big obstacle to the penetration of anti-cancer nanomedicine, which mainly occurs in the following situations: (1) vascular abnormality of solid tumors; (2) lymphatic vessel abnormality of solid tumors; and (3) dense extracellular matrix of solid tumors, which greatly impede the penetration of anticancer nanomedicine into the depths of the tumor tissues, and make it difficult for nanomedicine to exert effective anti-cancer effects. The more studied strategies to promote tumor penetration of anti-cancer nanomedicines usually employ regulation of TME and optimization of the physical properties of NPs.^{137–141} RNA or RNA-related liquid–liquid phase separation methods may be used to provide novel approaches to regulating TME.¹⁴² Xing *et al.*¹⁴³ introduced cationic polymers into living cells, which were then combined with negatively charged TGF- β 1 mRNA, and liquid–liquid phase separation occurred, preventing the translation of TGF- β 1 mRNA. As a result, the immunosuppressive ability of tumor cells in TME was reduced, triggering significant anti-tumor responses and improving the efficiency of tumor immunotherapy. In recent years, many advanced strategies to optimize the physicochemical properties of NPs for




Fig. 12 (a) Schematic representation of dual-targeted mRNA nanoformulations based on PBAE and hyaluronic acid. (b) Immunofluorescence staining of lung tissue was performed to assess the location of target protein expression. Luc proteins are indicated in pink. (c) The ex vivo bioluminescence images of different major organs after 24 h of inhalation of the nanoformulations. (d) Quantitative analysis of the luminescent flux emitted by different organs. (e) Fluorescence images of mouse lung tissue sections after inhalation of empty nanoformulations or loaded p53-mRNA nanoformulations (nuclei, blue; p53 protein, orange). (f) Quantitative analysis of p53 signaling in lung tissue sections after inhalation of p53-loaded mRNA nanoformulations.¹³³ Copyright 2023, National Academy of Sciences.

enhancing tumor penetration have been proposed, such as the design of nano-based delivery systems with mucosal adhesion.^{144,145} Functional groups, such as amine and sulphydryl groups, can effectively prolong the residence time in tumor-containing organs, thereby promoting the uptake and penetration of NPs into tumor tissues. Kong *et al.*¹⁴⁶ modified the PLGA vector with sulphydryl group to form disulfide bonds with cysteines in bladder tissue mucus glycoproteins, conferring mucosal adhesion properties to this system. This property prolonged the exposure of mRNA encoding the tumor suppressor KDM6A to bladder tumors. The system was internalized into bladder cancer cells *via* macropinocytosis, effectively inhibiting bladder tumor growth and metastasis.

Transcytosis, being an inherent cellular function, has garnered interest as a possible remedy for the drawbacks related to passive delivery. Transcytosis is a transcellular transport of molecules facilitated by electrostatic adsorption or receptor-mediated endocytosis. It has recently been recognized that the active transport of NPs into solid tumors through transcytosis is an effective way to overcome the biological barriers of the blood vessel wall and tumor extracellular matrix.^{147–149} Various transcytosis-based nanocarriers have been developed for

small-molecule and biomacromolecular drug delivery.^{150–152} The transcytosis-based strategy may be a promising way for mRNA delivery.

Nanomedicines also need to penetrate various biological barriers in the body during delivery, the most challenging is the brain blood barrier (BBB), as the tight junctions between cells strictly control substance transportation.¹⁵³ Transcytosis-based gene delivery systems have been developed to overcome BBB. Following the identification of the BBB's increased transport mechanism, a thorough investigation into the potential applications of this route in brain tumor treatment has commenced.¹⁵⁴ Liu *et al.*¹³ proposed a PEI-poly-L-lysine (PLL)-erythrocyte membrane-based PTEN mRNA delivery system. This system specifically bound the low-density lipoprotein receptor family overexpressed in BBB endothelial and brain tumor cells, utilizing receptor-mediated transcytosis for BBB penetration. The erythrocyte surface was doped with ApoE peptides, which further enhanced BBB penetration and GBM cell targeting. Notably, this system is the first polymer-based mRNA delivery system to overcome the BBB and achieve brain tumor cell targeting (Fig. 13). Kumthekar *et al.*¹⁵⁵ developed a gold NP-based spherical nucleic acid (SNA) delivery system to




Fig. 13 (a) Schematic diagram of PEI-PLL-erythrocyte membrane-encapsulated mRNA for the preparation of functionalized biomimetic NPs. (b) Mechanisms of transfection and antitumor induction by BBB-overexpressed receptor-mediated transcytosis at low pH endosomal escape and mRNA release. (c) Penetration of this polymer mimetic NPs in 3D U87MG tumor spheroids. (d) Biodistribution of major organs 4 h after intravenous injection of polymer-mimicking NPs-mRNA or naked mRNA. (e) TUNEL staining of brain tissue from mice on day 20. (f) H&E staining of brain tissue from mice on day 20.¹³ Copyright 2023, adapted with permission from Elsevier.

Table 2 Advanced delivery system improvement strategies

Advanced delivery	Specific site of action	Backbone type	Targeting strategies	Ref.
Cancer-selective and intracellular delivery	U87 cells	cRGD-PEG-PLL-PNIPAM	Receptor specific recognition	100
	APCs	PBAE	Oligopeptide mRNA terminal modification	103
Organ-targeted mRNA delivery	Splenic DCs	PBAE	Adjuvant co-delivery	104
	Splenic T cells	bAC-CART	Chemical modification	111
Tissue penetrating mRNA delivery	Liver	DMP	Receptor specific recognition	126
	Lungs, spleen, and liver	LNP	SORT strategy	127 and 128
Tissue penetrating mRNA delivery	Lungs, spleen, and liver	IAJD	Primary structure of the hydrophobic fraction	129
	Spleen and lymph nodes	ZPP	Charge reversal	36
Tissue penetrating mRNA delivery	Spleen	Quaternium lipid-like molecule	Charge reversal	10
	Lung	PBAE-PEG	Administration by inhalation	133
Tissue penetrating mRNA delivery	Lung	PBAE	Administration by inhalation	134
	TME	PEI	Intracellular mRNA phase separation	143
Tissue penetrating mRNA delivery	TME	PLGA	Chemical modification	146
	BBB	PEI-PLL	Receptor-mediated transcytosis	13
Tissue penetrating mRNA delivery	BBB	Gold NPs	Receptor-mediated transcytosis	155
	Nasal cavity mucous membrane layer	PAsp	PCI technology	163
Tissue penetrating mRNA delivery	Skin barrier	PVP	Dissolvable microneedle delivery platform	168

treat GBM. It was shown that class A scavenger receptors on BBB endothelial cells facilitate the recognition of siRNA oligonucleotide corona in this system. Subsequently, the SNA penetrates the BBB and the tumor *via* transcytosis. After the SNA enters the cancer cells, the expression of oncogenes is suppressed and triggers cancer cell death. This study marks the first nanomedicine that penetrated the BBB by intravenous injection and entered the Phase 0 clinical study. However, achieving drug delivery across the BBB remains a major challenge, and there are few reports of polymer-delivered mRNAs in this area. The delivery design strategies described above can serve as references for future polymer research. In addition, we can also consider coating the polymer surface with peptides that facilitate BBB penetration or connecting neurotransmitters to act as “guides” when penetrating the BBB.^{156,157}

Many biological barriers in the body cause the efficacy of mRNA vaccines to be affected by the site and route of administration.¹⁵⁸ Therefore, some strategies administer therapeutic vaccines directly at or near the disease site.^{146,159} Intranasal delivery is widely used in treating brain and lung tumors due to its specific spatial targeting effect.^{132,160,161} However, a major problem in developing intranasal mRNA delivery agents is effectively penetrating antigens into the nasal mucosal layer.¹⁶² Jeong *et al.*¹⁶³ used photochemical internalization (PCI) technology to generate ROS at specific wavelengths of light, which destabilizes endosomal membranes along with cationic polymers. The PCI technology permits polymeric NPs to penetrate the nasal mucosal layer more efficiently and deliver the mRNA to the lungs.

In addition to delivering mRNA in vector-encapsulated form, subcutaneous delivery of naked mRNA is considered more efficient.^{164–166} However, naked mRNA is very susceptible

to enzymatic degradation during delivery. In addition, the negative charge of the mRNA makes it difficult to enter the cell as it experiences electrostatic repulsion at the cell membrane. Dissolving microneedles are often used as a transdermal medication delivery platform. The platform is typically made of excipients and water-soluble polymers, allowing mRNA to penetrate the skin’s viable layer, break down, and be released.^{167,168} Koh *et al.*¹⁶⁸ demonstrated for the first time that low molecular weight polyvinylpyrrolidone (PVP) is used for the fabrication of solubilized microneedle RNAPatch and maintains sufficient stability of the mRNA, with its transfection efficiency increasing with the depth of delivery. The microneedles, when applied to the E.G7-OVA immunotherapy model, retarded tumor growth more effectively than subcutaneous injection, induced equivalent prophylactic cellular and humoral immunity, and showed higher mean antibody titers.

Although some strategies to optimize penetration have been reported in recent years, their efficacy remains to be improved due to the specificity of TME and the biological barrier *in vivo* (Table 2). Future studies could focus on the nature of TME and the depth of penetration of NPs across biological barriers. Bioengineering strategies can be considered to optimize the design of polymer-based mRNA delivery systems, enhance penetration of the biological barrier, and improve tissue targeting.

4. Perspective

Cancer is one of the leading causes of mortality around the globe. Cancer-related fatalities are anticipated to increase to 13.1 million by 2030.¹⁶⁹ Despite the great efforts made to over-

come cancer, the results so far have been unsatisfactory. Traditional cancer treatments include surgical resection,¹⁷⁰ radiotherapy and chemotherapy.^{171,172} However, existing clinical treatments are unable to effectively deal with metastasis and recurrence of tumors. Treatments that can completely reverse and inhibit the growth of tumors have yet to be developed. Compared with traditional vaccine approaches, mRNA vaccine technology has many advantages:^{26,173} (1) shorter development cycle. (2) Dual immunization mechanism with inherent immunostimulatory properties and adjuvant action. (3) Higher safety. Most existing cutting-edge research on mRNAs is based on lipid-based delivery systems. Several liposomes have entered clinical trials of mRNA vaccines for the treatment of cancer, such as NCT02410733 and NCT04534205, etc.^{174–176} Patients currently receiving these therapies do show encouraging clinical efficacy in studies, but many clinical trials of mRNA cancer vaccines are still in the early stages of research. Polymer-based mRNA delivery systems have yet to be utilized on a large scale in clinical treatments. However, the system is characterized by simple synthesis, precise and controllable physicochemical properties, and penetration of biological barriers. Due to these advantages, polymer-based mRNA delivery systems have a non-negligible potential in mRNA cancer therapy.

Nevertheless, the application of polymer-based mRNA delivery systems to the treatment of cancer is still full of challenges. Within this field, researchers are continuously working to develop systems that can effectively deliver mRNA to tumor cells. These systems must comprehensively consider the properties of polymeric NPs, including the composition, size, stiffness, and surface charge.^{112,127,177} These properties may affect the physiological state and the immune system. In addition, due to the tunable and modifiable nature of polymers, the rational design of polymer-based mRNA delivery systems should emphasize precise delivery and efficient biological barrier penetration. Future research on mRNA delivery platforms will continue to focus on improving efficiency and minimizing side effects for highly targeted and safe delivery. In order to achieve effective mRNA delivery, these properties need to be finely regulated. These regulations should ensure that the mRNA can safely penetrate the biological barrier and ultimately reach the inside of the tumor cell to fulfill its therapeutic role. The designing and in-depth understanding of NP properties is critical, as they directly impact mRNA delivery efficiency and safety.

Meanwhile, designing polymeric NPs that can successfully penetrate physiological barriers is essential, but addressing the associated challenges cannot be ignored. For example, the understanding of the interactions between polymeric NPs and complex TMEs remains incomplete.¹⁷⁸ Since tumor tissue is a highly complex and heterogeneous microenvironment characterized by hypoxia, abnormal vascular system, dense extracellular matrix, overexpression of immunosuppressive proteins and abnormal metabolic regulation.¹⁷⁹ Therefore a deeper understanding of the behavior of polymeric NPs in complex physiological barriers could provide potential strategies to improve their mRNA delivery efficiency.

In cancer treatment, precision and personalized therapies have been important trends in medicine in recent years. This brings more efficient and targeted treatment options for cancer patients.¹⁸⁰ With the rapid advancement of genome sequencing technology and the cross-application of big data science, the concepts of precision medicine and personalized treatment are gradually gaining popularity.^{181,182} The core of precision medicine is the “three right things”: the right patient, the right dose, and the right drug. This means that treatment needs to be patient-specific, using the right dose of the right drug. Through genetic sequencing, it is possible to find the target of a cancer patient’s genetic mutation and then use targeted drugs for precise treatment. Several studies have been reported on the use of nanomaterials for precision medicine.^{183–185} For example, Siemer *et al.*¹⁸⁵ used computational modeling and sequencing techniques to determine the mechanism of cisplatin resistance in head and neck cancer tumor cells. Poly(sarcosine)-based polymeric NPs loaded with cisplatin were constructed for the purpose of overcoming drug resistance. In the future, mRNA delivery technologies can be considered to provide strong support for personalized treatment options. In particular, polymer-based mRNA delivery systems can precisely deliver specific mRNA molecules into tumor cells, thus enabling targeted therapy against specific gene mutations. This treatment modality has the potential to significantly improve therapeutic efficacy and reduce side effects.

In this review, significant advances in polymer-based mRNA delivery systems were elucidated. Past and ongoing studies have demonstrated that polymer-based mRNA delivery systems have great potential for clinical applications. Additionally, advanced delivery strategies are also discussed, which can inform the design of future polymer-based delivery systems to achieve precise targeted delivery. However, to realize the potential for truly effective clinical translation of polymer-based mRNA delivery systems, the delivery challenges mentioned above must be addressed through sustained research.

Author contributions

Qianyu Wan was responsible for writing the manuscript, while corresponding authors. Xuanrong Sun and Zhuxian Zhou were responsible for conceptualizing the ideas, and Yuji Sun, Xuanrong Sun and Zhuxian Zhou all made suggestions. All authors edited and approved the final manuscript.

Consent for publication

We have included 9 figures (Fig. 5–8 and 10–13) from previously published literature with required copyright permission from the copyright owners. We have mentioned this in the manuscript with appropriate citations. Fig. 1, 2, 3 and 9 were created with biorender.com.

Conflicts of interest

The authors declare no conflict of interest.

Acknowledgements

We thank the National Natural Science Foundation of China (52073249, 52373158 and 22075247), the National Key Research and Development Program of China (2021YFA1201200), and the Zhejiang Provincial Key Research and Development Program (2020C01123).

References

- 1 K. Leppek, R. Das and M. Barna, *Nat. Rev. Mol. Cell Biol.*, 2018, **19**, 158–174.
- 2 R. Balakrishnan, M. Mori, I. Segota, Z. Zhang, R. Aebersold, C. Ludwig and T. Hwa, *Science*, 2022, **378**, eabk2066.
- 3 Z. Meng, J. O'Keeffe-Ahern, J. Lyu, L. Pierucci, D. Zhou and W. Wang, *Biomater. Sci.*, 2017, **5**, 2381–2392.
- 4 U. Sahin, K. Karikó and Ö. Türeci, *Nat. Rev. Drug Discovery*, 2014, **13**, 759–780.
- 5 X. Han, M.-G. Alameh, K. Butowska, J. J. Knox, K. Lundgreen, M. Ghattas, N. Gong, L. Xue, Y. Xu, M. Lavertu, P. Bates, J. Xu, G. Nie, Y. Zhong, D. Weissman and M. J. Mitchell, *Nat. Nanotechnol.*, 2023, **18**, 1105–1114.
- 6 A. García, G. Maldonado, J. L. González, Y. Svitkin, D. Cantú, A. García-Carrancá, N. Sonenberg and G. Hernández, *Proc. Natl. Acad. Sci. U. S. A.*, 2021, **118**, 2108359118.
- 7 R. T. Shroff, P. Chalasani, R. Wei, D. Pennington, G. Quirk, M. V. Schoenle, K. L. Peyton, J. L. Uhrlaub, T. J. Ripperger, M. Jergović, S. Dalgai, A. Wolf, R. Whitmer, H. Hammad, A. Carrier, A. J. Scott, J. Nikolic-Žugich, M. Worobey, R. Sprissler, M. Dake, B. J. LaFleur and D. Bhattacharya, *Nat. Med.*, 2021, **27**, 2002–2011.
- 8 C. Liu, Q. Shi, X. Huang, S. Koo, N. Kong and W. Tao, *Nat. Rev. Cancer*, 2023, **23**, 526–543.
- 9 T. Soundara Rajan, A. Gugliandolo, P. Bramanti and E. Mazzon, *Int. J. Mol. Sci.*, 2020, **21**, 6514.
- 10 R. Zhang, S. Shao, Y. Piao, J. Xiang, X. Wei, Z. Zhang, Z. Zhou, J. Tang, N. Qiu, X. Xu, Y. Liu and Y. Shen, *Adv. Mater.*, 2023, **35**, 2303614.
- 11 N. Chaudhary, D. Weissman and K. A. Whitehead, *Nat. Rev. Drug Discovery*, 2021, **20**, 817–838.
- 12 K. Servick, *Science*, 2020, **370**, 1388–1389.
- 13 Y. Liu, D. Zhang, Y. An, Y. Sun, J. Li, M. Zheng, Y. Zou and B. Shi, *Nano Today*, 2023, **49**, 101790.
- 14 K. Lundstrom, *Diseases*, 2018, **6**, 42.
- 15 W. Doerfler, *Virus Res.*, 2021, **302**, 198466.
- 16 R. Yang, Y. Deng, B. Huang, L. Huang, A. Lin, Y. Li, W. Wang, J. Liu, S. Lu, Z. Zhan, Y. Wang, R. A, W. Wang, P. Niu, L. Zhao, S. Li, X. Ma, L. Zhang, Y. Zhang, W. Yao, X. Liang, J. Zhao, Z. Liu, X. Peng, H. Li and W. Tan, *Signal Transduction Targeted Ther.*, 2021, **6**, 213.
- 17 M. Kakran, M. Muratani, W. J. Tng, H. Liang, D. B. Trushina, G. B. Sukhorukov, H. H. Ng and M. N. Antipina, *J. Mater. Chem. B*, 2015, **3**, 5842–5848.
- 18 J. W. Schott, D. Hoffmann and A. Schambach, *Curr. Opin. Pharmacol.*, 2015, **24**, 135–146.
- 19 M. C. Milone and U. O'Doherty, *Leukemia*, 2018, **32**, 1529–1541.
- 20 M. Watanabe, Y. Nishikawaji, H. Kawakami and K. I. Kosai, *Viruses*, 2021, **13**, 2502.
- 21 S. Wu, J. Huang, Z. Zhang, J. Wu, J. Zhang, H. Hu, T. Zhu, J. Zhang, L. Luo, P. Fan, B. Wang, C. Chen, Y. Chen, X. Song, Y. Wang, W. Si, T. Sun, X. Wang, L. Hou and W. Chen, *Lancet Infect. Dis.*, 2021, **21**, 1654–1664.
- 22 G. N. Nguyen, J. K. Everett, S. Kafle, A. M. Roche, H. E. Raymond, J. Leiby, C. Wood, C.-A. Assenmacher, E. P. Merricks, C. T. Long, H. H. Kazazian, T. C. Nichols, F. D. Bushman and D. E. Sabatino, *Nat. Biotechnol.*, 2021, **39**, 47–55.
- 23 J. N. Warnock, C. Daigre and M. Al-Rubeai, *Methods Mol. Biol.*, 2011, **737**, 1–25.
- 24 M. Jeong, Y. Lee, J. Park, H. Jung and H. Lee, *Adv. Drug Delivery Rev.*, 2023, **200**, 114990.
- 25 A. F. Rodrigues, C. Rebelo, S. Simões, C. Paulo, S. Pinho, V. Francisco and L. Ferreira, *Adv. Sci.*, 2023, **10**, 2205475.
- 26 S. Chen, X. Huang, Y. Xue, E. Álvarez-Benedicto, Y. Shi, W. Chen, S. Koo, D. J. Siegwart, Y. Dong and W. Tao, *Nat. Rev. Methods Primers*, 2023, **3**, 63.
- 27 Y. Liang, J. Zhang, C. Xu, J. Wang, W. Han, J. Yang, S. Wu, J. An, J. Liu, Z. Zhang, J. Shi and K. Zhang, *ACS Nano*, 2023, **17**, 15025–15043.
- 28 J. C. Kaczmarek, A. K. Patel, K. J. Kauffman, O. S. Fenton, M. J. Webber, M. W. Heartlein, F. DeRosa and D. G. Anderson, *Angew. Chem., Int. Ed.*, 2016, **55**, 13808–13812.
- 29 J. C. Kaczmarek, A. K. Patel, L. H. Rhym, U. C. Palmiero, B. Bhat, M. W. Heartlein, F. DeRosa and D. G. Anderson, *Biomaterials*, 2021, **275**, 120966.
- 30 M. A. Islam, E. K. G. Reesor, Y. Xu, H. R. Zope, B. R. Zetter and J. Shi, *Biomater. Sci.*, 2015, **3**, 1519–1533.
- 31 W. Zhang, A. Mehta, Z. Tong, L. Esser and N. H. Voelcker, *Adv. Sci.*, 2021, **8**, 2003937.
- 32 Y. Zhou, Z. Peng, E. S. Seven and R. M. Leblanc, *J. Controlled Release*, 2018, **270**, 290–303.
- 33 C. G. Zamboni, K. L. Kozielski, H. J. Vaughan, M. M. Nakata, J. Kim, L. J. Higgins, M. G. Pomper and J. J. Green, *J. Controlled Release*, 2017, **263**, 18–28.
- 34 M. Zoulikha, Q. Xiao, G. F. Boafo, M. A. Sallam, Z. Chen and W. He, *Acta Pharm. Sin. B*, 2022, **12**, 600–620.
- 35 P. Huang, L. Jiang, H. Pan, L. Ding, B. Zhou, M. Zhao, J. Zou, B. Li, M. Qi, H. Deng, Y. Zhou and X. Chen, *Adv. Mater.*, 2023, **35**, 2207471.
- 36 S. Liu, X. Wang, X. Yu, Q. Cheng, L. T. Johnson, S. Chatterjee, D. Zhang, S. M. Lee, Y. Sun, T. C. Lin,

J. L. Liu and D. J. Siegwart, *J. Am. Chem. Soc.*, 2021, **143**, 21321–21330.

37 A. Jarzębińska, T. Pasewald, J. Lambrecht, O. Mykhaylyk, L. Kümmelring, P. Beck, G. Hasenpusch, C. Rudolph, C. Plank and C. Dohmen, *Angew. Chem., Int. Ed.*, 2016, **55**, 9591–9595.

38 W. Yang, L. Mixich, E. Boonstra and H. Cabral, *Adv. Healthcare Mater.*, 2023, **12**, 2202688.

39 Z. Zhou, X. Liu, D. Zhu, Y. Wang, Z. Zhang, X. Zhou, N. Qiu, X. Chen and Y. Shen, *Adv. Drug Delivery Rev.*, 2017, **115**, 115–154.

40 P. Huang, H. Deng, Y. Zhou and X. Chen, *Matter*, 2022, **5**, 1670–1699.

41 E. Rohner, R. Yang, K. S. Foo, A. Goedel and K. R. Chien, *Nat. Biotechnol.*, 2022, **40**, 1586–1600.

42 A. K. Blakney, P. F. McKay, K. Hu, K. Samnuan, N. Jain, A. Brown, A. Thomas, P. Rogers, K. Polra, H. Sallah, J. Yeow, Y. Zhu, M. M. Stevens, A. Geall and R. J. Shattock, *J. Controlled Release*, 2021, **338**, 201–210.

43 S. Uchida, C. Y. J. Lau, M. Oba and K. Miyata, *Adv. Drug Delivery Rev.*, 2023, **199**, 114972.

44 S. Nimesh, *Curr. Clin. Pharmacol.*, 2012, **7**, 121–130.

45 J. Cai, Y. Yue, Y. Wang, Z. Jin, F. Jin and C. Wu, *J. Controlled Release*, 2016, **238**, 71–79.

46 A. Akinc, M. Thomas, A. M. Klibanov and R. Langer, *J. Gene Med.*, 2005, **7**, 657–663.

47 G. Chen, B. Zhao, E. F. Ruiz and F. Zhang, *Theranostics*, 2022, **12**, 4081–4109.

48 J. Zhou, J. W. Yockman, S. W. Kim and S. E. Kern, *Pharm. Res.*, 2007, **24**, 1079–1087.

49 R. R. Sawant, S. K. Sriraman, G. Navarro, S. Biswas, R. A. Dalvi and V. P. Torchilin, *Biomaterials*, 2012, **33**, 3942–3951.

50 J. Li, Y. Wu, J. Xiang, H. Wang, Q. Zhuang, T. Wei, Z. Cao, Q. Gu, Z. Liu and R. Peng, *Chem. Eng. J.*, 2023, **456**, 140930.

51 L. Tan, T. Zheng, M. Li, X. Zhong, Y. Tang, M. Qin and X. Sun, *Drug Delivery Transl. Res.*, 2020, **10**, 678–689.

52 M. Neu, D. Fischer and T. Kissel, *J. Gene Med.*, 2005, **7**, 992–1009.

53 T. Wu, L. Wang, S. Ding and Y. You, *Macromol. Biosci.*, 2017, **17**, 1700114.

54 H. Debus, P. Baumhof, J. Probst and T. Kissel, *J. Controlled Release*, 2010, **148**, 334–343.

55 S. Taranejoo, R. Chandrasekaran, W. Cheng and K. Hourigan, *Carbohydr. Polym.*, 2016, **153**, 160–168.

56 J. W. Park, K. H. Bae, C. Kim and T. G. Park, *Biomacromolecules*, 2011, **12**, 457–465.

57 C. Martins, F. Sousa, F. Araújo and B. Sarmento, *Adv. Healthcare Mater.*, 2018, **7**, 1701035.

58 T. Bus, A. Traeger and U. S. Schubert, *J. Mater. Chem. B*, 2018, **6**, 6904–6918.

59 B. Du, H. Yin, Y. Chen, W. Lin, Y. Wang, D. Zhao, G. Wang, X. He, J. Li, Z. Li, F. Luo, H. Tan and Q. Fu, *J. Mater. Chem. B*, 2020, **8**, 4434–4446.

60 H. K. Makadia and S. J. Siegel, *Polymers*, 2011, **3**, 1377–1397.

61 Y. Xiao, J. Chen, H. Zhou, X. Zeng, Z. Ruan, Z. Pu, X. Jiang, A. Matsui, L. Zhu, Z. Amoozgar, D. S. Chen, X. Han, D. G. Duda and J. Shi, *Nat. Commun.*, 2022, **13**, 758.

62 H. Guerrero-Cázares, S. Y. Tzeng, N. P. Young, A. O. Abutaleb, A. Quiñones-Hinojosa and J. J. Green, *ACS Nano*, 2014, **8**, 5141–5153.

63 P. Dosta, N. Segovia, A. Cascante, V. Ramos and S. Borrós, *Acta Biomater.*, 2015, **20**, 82–93.

64 K. L. Kozielski, S. Y. Tzeng, B. A. De Mendoza and J. J. Green, *ACS Nano*, 2014, **8**, 3232–3241.

65 S. Y. Neshat, C. H. R. Chan, J. Harris, O. M. Zmily, S. Est-Witte, J. Karlsson, S. R. Shannon, M. Jain, J. C. Doloff, J. J. Green and S. Y. Tzeng, *Biomaterials*, 2023, **300**, 122185.

66 L. Yang and Y. Zhang, *J. Hematol. Oncol.*, 2017, **10**, 58.

67 A. Mantovani, F. Marchesi, A. Malesci, L. Laghi and P. Allavena, *Nat. Rev. Clin. Oncol.*, 2017, **14**, 399–416.

68 W. D. Tap, Z. A. Wainberg, S. P. Anthony, P. N. Ibrahim, C. Zhang, J. H. Healey, B. Chmielowski, A. P. Staddon, A. L. Cohn, G. I. Shapiro, V. L. Keedy, A. S. Singh, I. Puzanov, E. L. Kwak, A. J. Wagner, D. D. Von Hoff, G. J. Weiss, R. K. Ramanathan, J. Zhang, G. Habets, Y. Zhang, E. A. Burton, G. Visor, L. Sanftner, P. Severson, H. Nguyen, M. J. Kim, A. Marimuthu, G. Tsang, R. Shellooe, C. Gee, B. L. West, P. Hirth, K. Nolop, M. van de Rijn, H. H. Hsu, C. Peterfy, P. S. Lin, S. Tong-Starksen and G. Bollag, *N. Engl. J. Med.*, 2015, **373**, 428–437.

69 N. Butowski, H. Colman, J. F. De Groot, A. M. Omuro, L. Nayak, P. Y. Wen, T. F. Cloughesy, A. Marimuthu, S. Haidar, A. Perry, J. Huse, J. Phillips, B. L. West, K. B. Nolop, H. H. Hsu, K. L. Ligon, A. M. Molinaro and M. Prados, *Neuro-Oncology*, 2016, **18**, 557–564.

70 F. Zhang, N. N. Parayath, C. I. Ene, S. B. Stephan, A. L. Koehne, M. E. Coon, E. C. Holland and M. T. Stephan, *Nat. Commun.*, 2019, **10**, 3974.

71 Y. Yan, H. Xiong, X. Zhang, Q. Cheng and D. J. Siegwart, *Biomacromolecules*, 2017, **18**, 4307–4315.

72 Y. Jiang, Q. Lu, Y. Wang, E. Xu, A. Ho, P. Singh, Y. Wang, Z. Jiang, F. Yang, G. T. Tietjen, P. Cresswell and W. M. Saltzman, *Nano Lett.*, 2020, **20**, 1117–1123.

73 M. K. Grun, A. Suberi, K. Shin, T. Lee, V. Gomerdinger, Z. M. Moscato, A. S. Piotrowski-Daspit and W. M. Saltzman, *Biomaterials*, 2021, **272**, 120780.

74 S. Chatterjee, E. Kon, P. Sharma and D. Peer, *Proc. Natl. Acad. Sci. U. S. A.*, 2024, **121**, 2307800120.

75 W. Chen, Y. Ma, X. Liu and D. Zhu, *Explor Target Antitumor Ther.*, 2022, **3**, 117–127.

76 A. Harguindey, D. W. Domaille, B. D. Fairbanks, J. Wagner, C. N. Bowman and J. N. Cha, *Adv. Mater.*, 2017, **29**, 1700743.

77 H. Xu, Q. Yao, C. Cai, J. Gou, Y. Zhang, H. Zhong and X. Tang, *J. Controlled Release*, 2015, **199**, 84–97.

78 Y. Meng and J. Wu, *ACS Appl. Mater. Interfaces*, 2021, **13**, 49658–49670.

79 X. Fan, H. Ren, X. Luo, P. Wang, G. Lv, H. Yuan, H. Li and Y. Yan, *J. Biomater. Appl.*, 2016, **30**, 1261–1272.

80 H. J. Kim, S. Ogura, T. Otabe, R. Kamegawa, M. Sato, K. Kataoka and K. Miyata, *ACS Cent. Sci.*, 2019, **5**, 1866–1875.

81 N. U. Dharmaratne, T. M. M. Jouaneh, M. K. Kiesewetter and R. T. Mathers, *Macromolecules*, 2018, **51**, 8461–8468.

82 J. Yum, B. S. Kim, S. Ogura, R. Kamegawa, M. Naito, Y. Yamasaki, H. J. Kim and K. Miyata, *J. Controlled Release*, 2022, **342**, 148–156.

83 Z. Zhou, X. Ma, C. J. Murphy, E. Jin, Q. Sun, Y. Shen, E. A. Van Kirk and W. J. Murdoch, *Angew. Chem., Int. Ed.*, 2014, **53**, 10949–10955.

84 J. Yang, K. Wang, Y. Zheng, Y. Piao, J. Wang, J. Tang, Y. Shen and Z. Zhou, *Angew. Chem., Int. Ed.*, 2022, **61**, 202202128.

85 G. Wang, Z. Zhou, Z. Zhao, Q. Li, Y. Wu, S. Yan, Y. Shen and P. Huang, *ACS Nano*, 2020, **14**, 4890–4904.

86 F. Bi, J. Zhang, Z. Wei, D. Yu, S. Zheng, J. Wang, H. Li, Z. Hua, H. Zhang and G. Yang, *Biomacromolecules*, 2022, **23**, 128–139.

87 D. Huang and D. Wu, *Mater. Sci. Eng., C*, 2018, **90**, 713–727.

88 S. Chowdhury, I. Toth and R. J. Stephenson, *Biomaterials*, 2022, **280**, 121303.

89 J. Chen, D. Zhu, X. Liu and L. Peng, *Acc. Mater. Res.*, 2022, **3**, 484–497.

90 F. Joubert, M. J. Munson, A. Sabirsh, R. M. England, M. Hemmerling, C. Alexander and M. B. Ashford, *J. Controlled Release*, 2023, **356**, 580–594.

91 S. Ndeupen, Z. Qin, S. Jacobsen, A. Bouteau, H. Estanbouli and B. Z. Igyártó, *iScience*, 2021, **24**, 103479.

92 K. Van der Jeught, S. De Koker, L. Bialkowski, C. Heirman, P. Tjok Joe, F. Perche, S. Maenhout, S. Bevers, K. Broos, K. Deswarte, V. Malard, H. Hammad, P. Baril, T. Benvegnù, P. A. Jaffrès, S. A. A. Kooijmans, R. Schiffelers, S. Lienenklaus, P. Midoux, C. Pichon, K. Breckpot and K. Thielemans, *ACS Nano*, 2018, **12**, 9815–9829.

93 S. Persano, M. L. Guevara, Z. Li, J. Mai, M. Ferrari, P. P. Pompa and H. Shen, *Biomaterials*, 2017, **125**, 81–89.

94 H. Xiong, S. Liu, T. Wei, Q. Cheng and D. J. Siegwart, *J. Controlled Release*, 2020, **325**, 198–205.

95 S. A. Dilliard and D. J. Siegwart, *Nat. Rev. Mater.*, 2023, **8**, 282–300.

96 Y. Zong, Y. Lin, T. Wei and Q. Cheng, *Adv. Mater.*, 2023, **35**, 2303261.

97 I. Canton and G. Battaglia, *Chem. Soc. Rev.*, 2012, **41**, 2718–2739.

98 Y. Hu, X. Liu, M. Ran, T. Yang, T. Li, Y. Wu, Y. Lin, Z. Qian and X. Gao, *Mater. Today Nano*, 2022, **17**, 100151.

99 J. Yoo, C. Park, G. Yi, D. Lee and H. Koo, *Cancers*, 2019, **11**, 640.

100 Q. Chen, R. Qi, X. Chen, X. Yang, S. Wu, H. Xiao and W. Dong, *Mol. Ther.*, 2017, **25**, 92–101.

101 L. B. Darragh and S. D. Karam, *Mol. Carcinog.*, 2022, **61**, 153–164.

102 S. Jhunjhunwala, C. Hammer and L. Delamarre, *Nat. Rev. Cancer*, 2021, **21**, 298–312.

103 C. Fornaguera, M. Guerra-Rebollo, M. Ángel Lázaro, C. Castells-Sala, O. Meca-Cortés, V. Ramos-Pérez, A. Cascante, N. Rubio, J. Blanco and S. Borrós, *Adv. Healthcare Mater.*, 2018, **7**, 1800335.

104 E. Ben-Akiva, J. Karlsson, S. Hemmati, H. Yu, S. Y. Tzeng, D. M. Pardoll and J. J. Green, *Proc. Natl. Acad. Sci. U. S. A.*, 2023, **120**, 2301606120.

105 B. V. Kumar, T. J. Connors and D. L. Farber, *Immunity*, 2018, **48**, 202–213.

106 P. Zhou, H. Shi, H. Huang, X. Sun, S. Yuan, N. M. Chapman, J. P. Connelly, S. A. Lim, J. Saravia, A. Kc, S. M. Pruitt-Miller and H. Chi, *Nature*, 2023, **624**, 154–163.

107 B. L. Cadilha, M. R. Benmebarek, K. Dorman, A. Oner, T. Lorenzini, H. Obeck, M. Vänttinen, M. Di Pilato, J. N. Pruessmann, S. Stoiber, D. Huynh, F. Märkl, M. Seifert, K. Manske, J. Suarez-Gosalvez, Y. Zeng, S. Lesch, C. H. Karches, C. Heise, A. Gottschlich, M. Thomas, C. Marr, J. Zhang, D. Pandey, T. Feuchtinger, M. Subklewe, T. R. Mempel, S. Endres and S. Kobold, *Sci. Adv.*, 2021, **7**, eabi5781.

108 K. M. Maalej, M. Merhi, V. P. Inchakalody, S. Mestiri, M. Alam, C. Maccalli, H. Cherif, S. Uddin, M. Steinhoff, F. M. Marincola and S. Dermime, *Mol. Cancer*, 2023, **22**, 20.

109 N. G. Holtzman, H. Xie, S. Bentzen, V. Kesari, A. Bukhari, F. El Chaer, F. Lutfi, J. Siglin, E. Hutnick, N. Gahres, K. Ruehle, H. Ahmad, C. Shanholz, M. H. Kocoglu, A. Z. Badros, J. A. Yared, N. M. Hardy, A. P. Rapoport and S. Dahiya, *Neuro-Oncology*, 2021, **23**, 112–121.

110 M. L. Schubert, M. Schmitt, L. Wang, C. A. Ramos, K. Jordan, C. Müller-Tidow and P. Dreger, *Ann. Oncol.*, 2021, **32**, 34–48.

111 Z. Li, L. Amaya, R. Pi, S. K. Wang, A. Ranjan, R. M. Waymouth, C. A. Blish, H. Y. Chang and P. A. Wender, *Nat. Commun.*, 2023, **14**, 6983.

112 Y. Hui, X. Yi, F. Hou, D. Wibowo, F. Zhang, D. Zhao, H. Gao and C. X. Zhao, *ACS Nano*, 2019, **13**, 7410–7424.

113 S. Hamdy, A. Haddadi, R. W. Hung and A. Lavasanifar, *Adv. Drug Delivery Rev.*, 2011, **63**, 943–955.

114 M. Zhang, H. Jiang, L. Wu, H. Lu, H. Bera, X. Zhao, X. Guo, X. Liu, D. Cun and M. Yang, *J. Controlled Release*, 2022, **352**, 422–437.

115 G. S. Naidu, S. B. Yong, S. Ramishetti, R. Rampado, P. Sharma, A. Ezra, M. Goldsmith, I. Hazan-Halevy, S. Chatterjee, A. Aitha and D. Peer, *Adv. Sci.*, 2023, **10**, 2301929.

116 M. Maugeri, M. Nawaz, A. Papadimitriou, A. Angerfors, A. Camponeschi, M. Na, M. Hölttä, P. Skantze, S. Johansson, M. Sundqvist, J. Lindquist, T. Kjellman, I. L. Mårtensson, T. Jin, P. Sunnerhagen, S. Östman, L. Lindfors and H. Valadi, *Nat. Commun.*, 2019, **10**, 4333.

117 N. Yoshinaga, S. Uchida, A. Dirisala, M. Naito, K. Koji, K. Osada, H. Cabral and K. Kataoka, *Adv. Healthcare Mater.*, 2022, **11**, 2102016.

118 X. Xu and T. Xia, *ACS Nanosci. Au*, 2023, **3**, 192–203.

119 S. T. LoPresti, M. L. Arral, N. Chaudhary and K. A. Whitehead, *J. Controlled Release*, 2022, **345**, 819–831.

120 V. Kumar, J. Qin, Y. Jiang, R. G. Duncan, B. Brigham, S. Fishman, J. K. Nair, A. Akinc, S. A. Barros and P. V. Kasperkovitz, *Mol. Ther. – Nucleic Acids*, 2014, **3**, 210.

121 B. L. Mui, Y. K. Tam, M. Jayaraman, S. M. Ansell, X. Du, Y. Y. Tam, P. J. Lin, S. Chen, J. K. Narayananair, K. G. Rajeev, M. Manoharan, A. Akinc, M. A. Maier, P. Cullis, T. D. Madden and M. J. Hope, *Mol. Ther. – Nucleic Acids*, 2013, **2**, 139.

122 C. Dobrowolski, K. Paunovska, M. Z. C. Hatit, M. P. Lokugamage and J. E. Dahlman, *Adv. Healthcare Mater.*, 2021, **10**, 2002022.

123 H. Wang, C. A. Thorling, X. Liang, K. R. Bridle, J. E. Grice, Y. Zhu, D. H. G. Crawford, Z. P. Xu, X. Liu and M. S. Roberts, *J. Mater. Chem. B*, 2015, **3**, 939–958.

124 Y. S. Zhu, K. Tang and J. Lv, *Trends Pharmacol. Sci.*, 2021, **42**, 857–869.

125 P. Lingasamy, A. Tobi, M. Haugas, H. Hunt, P. Paiste, T. Asser, T. Rätsep, V. R. Kotamraju, R. Bjerkvig and T. Teesalu, *Biomaterials*, 2019, **219**, 119373.

126 S. Lei, X. Chen, Y. Gao, M. Shuai, W. Zhou, J. Li, J. Wu, K. Men and X. Duan, *Adv. Funct. Mater.*, 2022, **32**, 2204342.

127 Q. Cheng, T. Wei, L. Farbiak, L. T. Johnson, S. A. Dilliard and D. J. Siegwart, *Nat. Nanotechnol.*, 2020, **15**, 313–320.

128 X. Wang, S. Liu, Y. Sun, X. Yu, S. M. Lee, Q. Cheng, T. Wei, J. Gong, J. Robinson, D. Zhang, X. Lian, P. Basak and D. J. Siegwart, *Nat. Protoc.*, 2023, **18**, 265–291.

129 D. Zhang, E. N. Atochina-Vasserman, J. Lu, D. S. Maurya, Q. Xiao, M. Liu, J. Adamson, N. Ona, E. K. Reagan, H. Ni, D. Weissman and V. Percec, *J. Am. Chem. Soc.*, 2022, **144**, 4746–4753.

130 S. T. LoPresti, M. L. Arral, N. Chaudhary and K. A. Whitehead, *J. Controlled Release*, 2022, **345**, 819–831.

131 M. Qiu, Y. Tang, J. Chen, R. Muriph, Z. Ye, C. Huang, J. Evans, E. P. Henske and Q. Xu, *Proc. Natl. Acad. Sci. U. S. A.*, 2022, **119**, 2116271119.

132 Q. Wan, X. Zhang, D. Zhou, R. Xie, Y. Cai, K. Zhang and X. Sun, *J. Nanobiotechnol.*, 2023, **21**, 215.

133 Z. Tang, X. You, Y. Xiao, W. Chen, Y. Li, X. Huang, H. Liu, F. Xiao, C. Liu, S. Koo, N. Kong and W. Tao, *Proc. Natl. Acad. Sci. U. S. A.*, 2023, **120**, 2304966120.

134 L. Rotolo, D. Vanover, N. C. Bruno, H. E. Peck, C. Zurlo, J. Murray, R. K. Noel, L. O'Farrell, M. Araínga, N. Orr-Burks, J. Y. Joo, L. C. S. Chaves, Y. Jung, J. Beyersdorf, S. Gumber, R. Guerrero-Ferreira, S. Cornejo, M. Thoresen, A. K. Olivier, K. M. Kuo, J. C. Gumbart, A. R. Woolums, F. Villinger, E. R. Lafontaine, R. J. Hogan, M. G. Finn and P. J. Santangelo, *Nat. Mater.*, 2023, **22**, 369–379.

135 Q. Sun, X. Sun, X. Ma, Z. Zhou, E. Jin, B. Zhang, Y. Shen, E. A. Van Kirk, W. J. Murdoch, J. R. Lott, T. P. Lodge, M. Radosz and Y. Zhao, *Adv. Mater.*, 2014, **26**, 7615–7621.

136 Q. Sun, Z. Zhou, N. Qiu and Y. Shen, *Adv. Mater.*, 2017, **29**, 1606628.

137 L. Li, M. Zhen, H. Wang, Z. Sun, X. Cao, J. Li, S. Liu, Z. Zhao, C. Zhou, C. Wang and C. Bai, *Nano Today*, 2023, **48**, 101702.

138 S. Ma, W. Xu, Y. Fei, D. Li, X. Jia, J. Wang and E. Wang, *Adv. Healthcare Mater.*, 2023, **12**, 2301413.

139 C. Hotz, T. R. Wagenaar, F. Gieseke, D. S. Bangari, M. Callahan, H. Cao, J. Diekmann, M. Diken, C. Grunwitz, A. Hebert, K. Hsu, M. Bernardo, K. Karikó, S. Kreiter, A. N. Kuhn, M. Levit, N. Malkova, S. Masciari, J. Pollard, H. Qu, S. Ryan, A. Selmi, J. Schlereth, K. Singh, F. Sun, B. Tillmann, T. Tolstykh, W. Weber, L. Wicke, S. Witzel, Q. Yu, Y. A. Zhang, G. Zheng, J. Lager, G. J. Nabel, U. Sahin and D. Wiederschain, *Sci. Transl. Med.*, 2021, **13**, eabc7804.

140 K. J. Hassett, J. Higgins, A. Woods, B. Levy, Y. Xia, C. J. Hsiao, E. Acosta, Ö. Almarsson, M. J. Moore and L. A. Brito, *J. Controlled Release*, 2021, **335**, 237–246.

141 S. Dong, Z. Feng, R. Ma, T. Zhang, J. Jiang, Y. Li, Y. Zhang, S. Li, X. Liu, X. Liu and H. Meng, *Nano Lett.*, 2023, **23**, 2137–2147.

142 S. Mehta and J. Zhang, *Nat. Rev. Cancer*, 2022, **22**, 239–252.

143 Z. Xing, J. Xue, X. Ma, C. Han, Z. Wang, S. Luo, C. Wang, L. Dong and J. Zhang, *J. Nanobiotechnol.*, 2022, **20**, 442.

144 C. Mugabe, Y. Matsui, A. I. So, M. E. Gleave, J. H. Baker, A. I. Minchinton, I. Manisali, R. Liggins, D. E. Brooks and H. M. Burt, *Clin. Cancer Res.*, 2011, **17**, 2788–2798.

145 Q. Zhang, K. G. Neoh, L. Xu, S. Lu, E. T. Kang, R. Mahendran and E. Chiong, *Langmuir*, 2014, **30**, 6151–6161.

146 N. Kong, R. Zhang, G. Wu, X. Sui, J. Wang, N. Y. Kim, S. Blake, D. De, T. Xie, Y. Cao and W. Tao, *Proc. Natl. Acad. Sci. U. S. A.*, 2022, **119**, 2112696119.

147 Q. Zhou, S. Shao, J. Wang, C. Xu, J. Xiang, Y. Piao, Z. Zhou, Q. Yu, J. Tang, X. Liu, Z. Gan, R. Mo, Z. Gu and Y. Shen, *Nat. Nanotechnol.*, 2019, **14**, 799–809.

148 S. Sindhwani, A. M. Syed, J. Ngai, B. R. Kingston, L. Maiorino, J. Rothschild, P. MacMillan, Y. Zhang, N. U. Rajesh, T. Hoang, J. L. Y. Wu, S. Wilhelm, A. Zilman, S. Gadde, A. Sulaiman, B. Ouyang, Z. Lin, L. Wang, M. Egeblad and W. C. W. Chan, *Nat. Mater.*, 2020, **19**, 566–575.

149 Z. Wang, Y. Sun, Y. Shen and Z. Zhou, *Adv. NanoBiomed. Res.*, 2023, 2300125.

150 H. Ren, Q. Hu, J. Yang, X. Zhou, X. Liu, J. Tang, H. Hu, Y. Shen and Z. Zhou, *Adv. Healthcare Mater.*, 2023, **12**, 2302210.

151 Y. Qin, G. Wang, L. Chen, Y. Sun, J. Yang, Y. Piao, Y. Shen and Z. Zhou, *Adv. Mater.*, 2023, 2302292.

152 H. Ren, Q. Hu, Y. Sun, X. Zhou, Y. Zhu, Q. Dong, L. Chen, J. Tang, H. Hu, Y. Shen and Z. Zhou, *Biomater. Sci.*, 2023, **11**, 7051–7061.

153 E. Nance, S. H. Pun, R. Saigal and D. L. Sellers, *Nat. Rev. Mater.*, 2022, **7**, 314–331.

154 L. Wang and S. Wilhelm, *Nat. Mater.*, 2023, **22**, 282–283.

155 P. Kumthekar, C. H. Ko, T. Paunesku, K. Dixit, A. M. Sonabend, O. Bloch, M. Tate, M. Schwartz, L. Zuckerman, R. Lezon, R. V. Lukas, B. Jovanovic, K. McCortney, H. Colman, S. Chen, B. Lai, O. Antipova, J. Deng, L. Li, S. Tommasini-Ghelfi, L. A. Hurley, D. Unruh, N. V. Sharma, M. Kandpal, F. M. Kouri, R. V. Davuluri, D. J. Brat, M. Muzzio, M. Glass, V. Vijayakumar, J. Heidel, F. J. Giles, A. K. Adams, C. D. James, G. E. Woloschak, C. Horbinski and A. H. Stegh, *Sci. Transl. Med.*, 2021, **13**, eabb3945.

156 F. Ma, L. Yang, Z. Sun, J. Chen, X. Rui, Z. Glass and Q. Xu, *Sci. Adv.*, 2020, **6**, eabb4429.

157 C. Fornaguera, M. Lázaro, P. Brugada-Vilà, I. Porcar, I. Morera, M. Guerra-Rebollo, C. Garrido, N. Rubio, J. Blanco, A. Cascante and S. Borrós, *Drug Delivery*, 2018, **25**, 472–483.

158 M. Saxena, S. H. van der Burg, C. J. M. Melief and N. Bhardwaj, *Nat. Rev. Cancer*, 2021, **21**, 360–378.

159 E. Blass and P. A. Ott, *Nat. Rev. Clin. Oncol.*, 2021, **18**, 215–229.

160 L. Tang, R. Zhang, Y. Wang, X. Zhang, Y. Yang, B. Zhao and L. Yang, *Acta Biomater.*, 2023, **155**, 521–537.

161 M. Sheinin, B. Jeong, R. K. Paidi and K. Pahan, *Cancers*, 2022, **14**, 5648.

162 D. Cahn, M. Amosu, K. Maisel and G. A. Duncan, *Nat. Rev. Bioeng.*, 2023, **1**, 83–84.

163 H. Jeong, H. Kim, Y. A. Kim, K. S. Kim and K. Na, *ACS Appl. Mater. Interfaces*, 2023, **15**, 56749–56759.

164 K. K. Phua, K. W. Leong and S. K. Nair, *J. Controlled Release*, 2013, **166**, 227–233.

165 N. Sultana, A. Magadum, Y. Hadas, J. Kondrat, N. Singh, E. Youssef, D. Calderon, E. Chepurko, N. Dubois, R. J. Hajjar and L. Zangi, *Mol. Ther.*, 2017, **25**, 1306–1315.

166 S. Kreiter, A. Selmi, M. Diken, M. Koslowski, C. M. Britten, C. Huber, O. Türeci and U. Sahin, *Cancer Res.*, 2010, **70**, 9031–9040.

167 S. C. Balmert, C. D. Carey, G. D. Falo, S. K. Sethi, G. Erdos, E. Korkmaz and L. D. Falo, Jr., *J. Controlled Release*, 2020, **317**, 336–346.

168 K. J. Koh, Y. Liu, S. H. Lim, X. J. Loh, L. Kang, C. Y. Lim and K. K. L. Phua, *Sci. Rep.*, 2018, **8**, 11842.

169 M. J. Thun, J. O. DeLancey, M. M. Center, A. Jemal and E. M. Ward, *Carcinogenesis*, 2010, **31**, 100–110.

170 K. Washington and F. Rocha, *Curr. Treat Options Oncol.*, 2021, **22**, 97.

171 Y. Pointreau, J. Biau, N. Delaby, J. Thariat and M. Lapeyre, *Cancer Radiother.*, 2022, **26**, 199–205.

172 I. Ali, W. A. Wani, K. Saleem and A. Haque, *Adv. Anticancer Agents Med. Chem.*, 2013, **13**, 296–306.

173 N. Pardi, M. J. Hogan, F. W. Porter and D. Weissman, *Nat. Rev. Drug Discovery*, 2018, **17**, 261–279.

174 C. L. Lorentzen, J. B. Haanen, Ö. Met and I. M. Svane, *Lancet Oncol.*, 2022, **23**, 450–458.

175 U. Sahin, P. Oehm, E. Derhovanessian, R. A. Jabulowsky, M. Vormehr, M. Gold, D. Maurus, D. Schwarck-Kokarakis, A. N. Kuhn, T. Omokoko, L. M. Kranz, M. Diken, S. Kreiter, H. Haas, S. Attig, R. Rae, K. Cuk, A. Kemmer-Brück, A. Breitkreuz, C. Tolliver, J. Caspar, J. Quinkhardt, L. Hebich, M. Stein, A. Hohberger, I. Vogler, I. Liebig, S. Renken, J. Sikorski, M. Leierer, V. Müller, H. Mitzel-Rink, M. Miederer, C. Huber, S. Grabbe, J. Utikal, A. Pinter, R. Kaufmann, J. C. Hassel, C. Loquai and Ö. Türeci, *Nature*, 2020, **585**, 107–112.

176 A. J. Barbier, A. Y. Jiang, P. Zhang, R. Wooster and D. G. Anderson, *Nat. Biotechnol.*, 2022, **40**, 840–854.

177 S. Egloff, A. Runser, A. Klymchenko and A. Reisch, *Small Methods*, 2021, **5**, 2000947.

178 Y. Huang, W. Xiao, S. Ahrari, M. Yu and J. Zheng, *Angew. Chem., Int. Ed.*, 2023, **62**, 202308909.

179 W. Zhen, R. R. Weichselbaum and W. Lin, *Adv. Mater.*, 2023, **35**, 2206370.

180 A. Wahida, L. Buschhorn, S. Fröhling, P. J. Jost, A. Schneeweiss, P. Lichter and R. Kurzrock, *Nat. Rev. Cancer*, 2023, **23**, 43–54.

181 J. C. Denny and F. S. Collins, *Cell*, 2021, **184**, 1415–1419.

182 S. M. Schüssler-Fiorenza Rose, K. Contrepois, K. J. Moneghetti, W. Zhou, T. Mishra, S. Mataraso, O. Dagan-Rosenfeld, A. B. Ganz, J. Dunn, D. Hornburg, S. Rego, D. Perelman, S. Ahadi, M. R. Sailani, Y. Zhou, S. R. Leopold, J. Chen, M. Ashland, J. W. Christle, M. Avina, P. Limcaoco, C. Ruiz, M. Tan, A. J. Butte, G. M. Weinstock, G. M. Slavich, E. Sodergren, T. L. McLaughlin, F. Haddad and M. P. Snyder, *Nat. Med.*, 2019, **25**, 792–804.

183 Y. Wang, S. Sun, Z. Zhang and D. Shi, *Adv. Mater.*, 2018, **30**, 1705660.

184 O. Adir, M. Poley, G. Chen, S. Froim, N. Krinsky, J. Shklover, J. Shainsky-Roitman, T. Lammers and A. Schroeder, *Adv. Mater.*, 2020, **32**, 1901989.

185 S. Siemer, T. A. Bauer, P. Scholz, C. Breder, F. Fenaroli, G. Harms, D. Dietrich, J. Dietrich, C. Rosenauer, M. Barz, S. Becker, S. Strieth, C. Reinhardt, T. Fauth, J. Hagemann and R. H. Stauber, *ACS Nano*, 2021, **15**, 18541–18556.